NDAC’s busy schedule
This article was originally published in The Tan Sheet
Executive Summary
A two-day joint meeting of the Nonprescription and Dermatologic & Ophthalmic Drugs Advisory Committees is scheduled for March 24-25. The two committees discussed labeling issues for OTC athlete's foot drugs during a meeting in May (1"The Tan Sheet," May 10, 2004, p. 10). NDAC also is scheduled to meet with the Endocrinologic & Metabolic Drugs Advisory Committee Jan. 13-14...
You may also be interested in...
OTC Athlete’s Foot Drug Labeling Changes Supported By NDAC Panel, Industry
Current labeling for OTC drugs for Tinea pedis (athlete's foot) may mislead consumers toward greater expectations of benefit and should be changed, FDA's Nonprescription Drugs and Dermatologic and Ophthalmic Drugs advisory committees agreed unanimously at a May 6 meeting in Rockville, Md
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.